Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Show More...

  • Website https://xiliotx.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.07 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 TTM
    Earnings Per Share USD -0.65 -2.07 -13.52 -13.52
    Dividends USD
    Payout Ratio % *
    Shares Mil 27.0 27.0 6.0 6.0
    Book Value Per Share * USD -4.99 6.75
    Free Cash Flow Per Share * USD -2.89
    Return on Assets % -27.6 -111.51 -59.6 -59.6
    Financial Leverage (Average) 1.17 1.17
    Return on Equity % -148.42 -148.42
    Return on Invested Capital % -105.35 -105.35
    Interest Coverage
    Current Ratio 9.81 0.93 15.85 15.85
    Quick Ratio 9.38 0.87 15.5 15.5
    Debt/Equity 0.11 0.11